Core Viewpoint - Abbott's quarterly earnings of $1.5 per share met the Zacks Consensus Estimate, showing an increase from $1.34 per share a year ago, with a slight earnings surprise of +0.20% [1] Financial Performance - Abbott reported revenues of $11.46 billion for the quarter ended December 2025, which was 2.76% below the Zacks Consensus Estimate and an increase from $10.97 billion year-over-year [2] - Over the last four quarters, Abbott has surpassed consensus EPS estimates three times but has only topped revenue estimates once [2] Stock Performance - Abbott shares have declined approximately 3.6% since the beginning of the year, contrasting with the S&P 500's gain of 0.4% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.19 on revenues of $11.17 billion, and for the current fiscal year, it is $5.67 on revenues of $48.01 billion [7] - The estimate revisions trend for Abbott was favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which Abbott belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8]